Mechanism of action of adrenergic drugs and recent updates

Enhancing competition in on-patent markets

“…The evidence of price competition is also available for European markets. For example, in a study of launch prices of 114 of 288 newly authorised outpatient medicines in Spain between 1997 and 2005, Puig-Junoy and López-Valcárcel (2014 [9]) found that launch prices of new entrants decreased as the number of competitors in the market increased. Additionally, analyses of sales data (2011-2017) for direct acting antivirals (DAAs) to treat hepatitis C in the US and seven European countries (UK, Austria, Belgium, France, Germany, Italy and Spain) showed that the market entry of two protease inhibitors followed by seven direct acting antivirals decreased prices by about 30% -60% (Sagonowsky, 2017 [10]), mitigating the budget impact and improving access to patients (Roediger et al, 2019[11]).…”